Onxeo

Onxeo operates as a clinical-phase biotech firm that develops innovative oncology medications aimed at disrupting tumor DNA repair functions. Their strategy revolves around a unique decoy agonist mechanism that disrupts DNA Damage Response. They concentrate on advancing pioneering compounds from translational research to proof-of-concept in human subjects for cancer types with significant unmet needs.